Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies

Article

Company News Release

SWINDON, U.K.

, and 

LAS VEGAS

, September 26, 2018-- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (“APIs”) for its Parkinson’s disease therapies. A proof of concept study will be conducted by Catalent at its Swindon, U.K. facility to evaluate GB Sciences’ clinical candidates GBS101, GBS102, and GBS103 using Catalent’s proprietary Zydis® Orally Disintegrating Tablet (ODT) technology.   GB Sciences’ three patent-pending APIs for Parkinson’s disease are complex mixtures containing up to nine individual components that function synergistically. Preclinical studies have shown that these cannabinoid-containing complex mixtures are more potent than would have been predicted by combining the activity of each individual compound.   “To prepare our Parkinson’s disease formulations for human clinical trials, we wanted the ease-of-use offered by Zydis ODTs for our Parkinson’s patients, many of whom may have difficulties in swallowing. Catalent’s proprietary delivery method also potentially offers consistent dosing for our complex cannabinoid- and terpenoid-containing APIs,” explained Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. “The creation of GB Sciences’ proprietary APIs in Zydis ODT formulations is a very important step towards readying them for our Exploratory IND filing and planned phase zero human trial for patients with mild to moderate Parkinson’s disease.”   Jonathan Arnold, President of Oral Drug Delivery at Catalent, added, “Dissolving rapidly in the mouth, ODTs are convenient and ease administration, offering an alternate dosage form for patients who have difficulty swallowing, as is sometimes the case with Parkinson’s disease, as well as with geriatric or pediatric patients.”   GB Sciences selected Catalent as its development partner due to its expertise in tackling formulation challenges, and ability to achieve the stability and dosing necessary for these novel complex mixtures. In addition to its Zydis technology, Catalent has early development and oral drug delivery solutions available for the efficient delivery of GB Sciences’ proprietary APIs.    

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit 

www.catalent.com

.  

More products. Better treatments. Reliably supplied.™

 

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: 

http://gbsciences.com

.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.